<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The treatment of malignant <z:hpo ids='HP_0100002'>pleural mesothelioma</z:hpo> (MPM) remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We present a prospective study of patients treated at our institution with neoadjuvant chemotherapy, extrapleural pneumonectomy (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e>), and radical radiotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients with MPM who were eligible for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e> and multimodality therapy were included in this study </plain></SENT>
<SENT sid="3" pm="."><plain>Staging was through computed tomography and <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography and computed tomography (PET/CT) scanning, video-assisted thoracoscopic surgery (VATS), and mediastinoscopy </plain></SENT>
<SENT sid="4" pm="."><plain>Our protocol involved three cycles of <z:chebi fb="2" ids="27899">cisplatin</z:chebi>-based neoadjuvant chemotherapy followed by extrapleural pneumonectomy and adjuvant radiotherapy (54 Gy) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were followed up every 3-6 months until <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: From March 2004 through October 2008, 25 patients were referred for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e> following neoadjuvant chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e> was performed in <z:hpo ids='HP_0000001'>all</z:hpo> but three patients, who were found to have T4 disease at surgery </plain></SENT>
<SENT sid="8" pm="."><plain>Surgical complications included <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (28%), bronchopleural <z:mpath ids='MPATH_70'>fistulas</z:mpath> (12 %), reoperations for <z:mp ids='MP_0001914'>bleeding</z:mp> (8%), <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> syndrome (4%), <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (4%), <z:mpath ids='MPATH_681'>septicemia</z:mpath> (4%), <z:e sem="disease" ids="C0042928" disease_type="Disease or Syndrome" abbrv="">vocal cord palsy</z:e> (4%), and <z:hpo ids='HP_0002277'>Horner's syndrome</z:hpo> (4%) </plain></SENT>
<SENT sid="9" pm="."><plain>The 30-day mortality was 4% </plain></SENT>
<SENT sid="10" pm="."><plain>Adjuvant radiotherapy was administered to 81% of patients after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Radiotherapy toxicities included <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, radiation <z:e sem="disease" ids="C0032285" disease_type="Disease or Syndrome" abbrv="PNEUM">pneumonitis</z:e>, pulmonary <z:mpath ids='MPATH_110'>embolus</z:mpath>, radiation <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, <z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">herpes zoster</z:e>, <z:e sem="disease" ids="C0026976" disease_type="Disease or Syndrome" abbrv="">transverse myelitis</z:e>, and late <z:hpo ids='HP_0002563'>constrictive pericarditis</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Median survival from diagnosis was 12.8 months (95% confidence interval 7.8-17.7 months) </plain></SENT>
<SENT sid="13" pm="."><plain>One-year survival was 54.5%; 2-year survival was 18.2% </plain></SENT>
<SENT sid="14" pm="."><plain>Disease progression occurred in 77.3% of patients </plain></SENT>
<SENT sid="15" pm="."><plain>Nodal status (N0 disease versus N1<z:chebi fb="31" ids="30226">-N2</z:chebi>) or histology (epithelioid versus biphasic) had no significant impact on survival </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: Despite recent advances in chemotherapy, surgery, and radiotherapy, survival rates remain low for patients with MPM completing multimodality therapy including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EPP</z:e> </plain></SENT>
</text></document>